High throughput screening of a library based on kinase inhibitor scaffolds against Mycobacterium tuberculosis H37Rv.

Kinase targets are being pursued in a variety of diseases beyond cancer, including immune and metabolic as well as viral, parasitic, fungal and bacterial. In particular, there is a relatively recent interest in kinase and ATP-binding targets in Mycobacterium tuberculosis in order to identify inhibitors and potential drugs for essential proteins that are not targeted by current drug regimens. Herein, we report the high throughput screening results for a targeted library of approximately 26,000 compounds that was designed based on current kinase inhibitor scaffolds and known kinase binding sites. The phenotypic data presented herein may form the basis for selecting scaffolds/compounds for further enzymatic screens against specific kinase or other ATP-binding targets in Mycobacterium tuberculosis based on the apparent activity against the whole bacteria in vitro.

[1]  N. Gray,et al.  Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.

[2]  S. Joshi,et al.  Synthesis of new 4-pyrrol-1-yl benzoic acid hydrazide analogs and some derived oxadiazole, triazole and pyrrole ring systems: a novel class of potential antibacterial and antitubercular agents. , 2008, European journal of medicinal chemistry.

[3]  C. Del Carpio,et al.  Three-dimensional quantitative structure-activity relationship (3 D-QSAR) and docking studies on (benzothiazole-2-yl) acetonitrile derivatives as c-Jun N-terminal kinase-3 (JNK3) inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[4]  M. Daffé,et al.  The mycobacterial cell envelope. , 2008 .

[5]  L. Collins,et al.  Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium , 1997, Antimicrobial agents and chemotherapy.

[6]  M. Vieth,et al.  Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. , 2004, Biochimica et biophysica acta.

[7]  M. Vieth,et al.  Kinomics: characterizing the therapeutically validated kinase space. , 2005, Drug discovery today.

[8]  P. Lograsso,et al.  Benzothiazoles as Rho-associated kinase (ROCK-II) inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[9]  R. Loddo,et al.  Synthesis and antiproliferative activity of 3-aryl-2-(1H-benzotriazol-1-yl)acrylonitriles. Part III. , 2002, European journal of medicinal chemistry.

[10]  D. Alessi,et al.  The nuts and bolts of AGC protein kinases , 2010, Nature Reviews Molecular Cell Biology.

[11]  M. Kurosu,et al.  Bacterial protein kinase inhibitors , 2010 .

[12]  L. Pettus,et al.  Small molecule p38 MAP kinase inhibitors for the treatment of inflammatory diseases: novel structures and developments during 2006-2008. , 2008, Current topics in medicinal chemistry.

[13]  Marco Bellinzoni,et al.  Mycobacterial Ser/Thr protein kinases and phosphatases: physiological roles and therapeutic potential. , 2008, Biochimica et biophysica acta.

[14]  A. Carta,et al.  Synthesis and antitubercular activity of 3-aryl substituted-2-[1H(2H)benzotriazol-1(2)-yl]acrylonitriles. , 2000, European journal of medicinal chemistry.

[15]  E. De Clercq,et al.  Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents. , 2008, European journal of medicinal chemistry.

[16]  Nick V Grishin,et al.  A comprehensive update of the sequence and structure classification of kinases , 2015 .

[17]  Nick V Grishin,et al.  Sequence and structure classification of kinases. , 2002, Journal of molecular biology.

[18]  G. Kéri,et al.  A novel drug discovery concept for tuberculosis: inhibition of bacterial and host cell signalling. , 2008, Immunology letters.

[19]  A. Siwek,et al.  Synthesis, Structure and Investigations of Tuberculosis Inhibition Activities of New 4-Methyl-1 -substituted-1H-1,2,4-triazole-5 (4H)-thione , 2008 .

[20]  S. Pattan,et al.  Synthesis and Evaluation of Some Novel Substituted 1,3,4‐Oxadiazole and Pyrazole Derivatives for Antitubercular Activity. , 2009 .

[21]  M. Pellecchia,et al.  Discovery of 2-(5-nitrothiazol-2-ylthio)benzo[d]thiazoles as novel c-Jun N-terminal kinase inhibitors. , 2009, Bioorganic & medicinal chemistry.

[22]  A. Dixit,et al.  2-Thiazolylimino/heteroarylimino-5-arylidene-4-thiazolidinones as new agents with SHP-2 inhibitory action. , 2008, Journal of medicinal chemistry.

[23]  G. V. Suresh Kumar,et al.  Synthesis of some novel 2-substituted-5-[isopropylthiazole] clubbed 1,2,4-triazole and 1,3,4-oxadiazoles as potential antimicrobial and antitubercular agents. , 2010, European journal of medicinal chemistry.

[24]  A. Doweyko,et al.  Benzothiazole based inhibitors of p38alpha MAP kinase. , 2008, Bioorganic & medicinal chemistry letters.

[25]  Carl A. Miecskowski,et al.  Structure/Function Studies of Ser/Thr and Tyr Protein Phosphorylation in Mycobacterium tuberculosis , 2006, Journal of Molecular Microbiology and Biotechnology.

[26]  P. Zarrinkar,et al.  Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor. , 2009, Journal of medicinal chemistry.

[27]  K. No,et al.  Synthesis of amide and urea derivatives of benzothiazole as Raf-1 inhibitor. , 2008, European journal of medicinal chemistry.

[28]  R. Reynolds,et al.  High Throughput Screening for Inhibitors of Mycobacterium tuberculosis H 37 Rv , 2012 .

[29]  G. Besra,et al.  EmbR2, a structural homologue of EmbR, inhibits the Mycobacterium tuberculosis kinase/substrate pair PknH/EmbR. , 2008, The Biochemical journal.

[30]  A. Alonso,et al.  Inhibition of Yersinia Tyrosine Phosphatase by Furanyl Salicylate Compounds* , 2005, Journal of Biological Chemistry.

[31]  Jeffrey Jie-Lou Liao,et al.  Molecular Recognition of Protein Kinase Binding Pockets for Design of Potent and Selective Kinase Inhibitors , 2007 .

[32]  Ivan Mijakovic,et al.  Tyrosine phosphorylation: an emerging regulatory device of bacterial physiology. , 2007, Trends in biochemical sciences.

[33]  L. Kremer,et al.  Division and cell envelope regulation by Ser/Thr phosphorylation: Mycobacterium shows the way , 2010, Molecular microbiology.

[34]  P. Furet,et al.  Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. , 1999, Pharmacology & therapeutics.

[35]  G. Müller,et al.  Second-generation kinase inhibitors , 2005, Expert opinion on therapeutic targets.

[36]  Maurizio Fermeglia,et al.  Antimycobacterial activity of new 3-substituted 5-(pyridin-4-yl)-3H-1,3,4-oxadiazol-2-one and 2-thione derivatives. Preliminary molecular modeling investigations. , 2005, Bioorganic & medicinal chemistry.

[37]  H. Foks,et al.  [Synthesis and tuberculostatic activity of reaction products 5-(2-,3- and 4-pyridil) -1,3,4-oxadiazol-2-thione with amines]. , 1993, Acta poloniae pharmaceutica.

[38]  A. Ullrich,et al.  Interplay between mycobacteria and host signalling pathways , 2004, Nature Reviews Microbiology.

[39]  A. Shafiee,et al.  Synthesis and antimycobacterial activity of some alkyl [5-(nitroaryl)-1,3,4-thiadiazol-2-ylthio]propionates. , 2006, Bioorganic & medicinal chemistry letters.

[40]  T. Cui,et al.  Uncovering new signaling proteins and potential drug targets through the interactome analysis of Mycobacterium tuberculosis , 2009, BMC Genomics.

[41]  J. Deutscher,et al.  Ser/Thr/Tyr Protein Phosphorylation in Bacteria – For Long Time Neglected, Now Well Established , 2006, Journal of Molecular Microbiology and Biotechnology.

[42]  P. Tomasec,et al.  The Inhibitor of Cyclin-Dependent Kinases, Olomoucine II, Exhibits Potent Antiviral Properties , 2010, Antiviral chemistry & chemotherapy.

[43]  3D QSAR Studies of 1, 3,4-oxadiazole Derivatives as Antimycobacterial Agents , 2009 .

[44]  Lynn Rasmussen,et al.  High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. , 2009, Tuberculosis.

[45]  M. A. Mueed,et al.  Scope of Mercuric Acetate Oxidation of Chalcones and the Antibacterial Activity of Resulting Aurones. , 2004 .

[46]  Shenlin Huang,et al.  Discovery of 2-amino-6-carboxamidobenzothiazoles as potent Lck inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[47]  A. Tyagi,et al.  20 The Role of Mycobacterial Kinases and Phosphatases in Growth, Pathogenesis, and Cell Wall Metabolism , 2008 .

[48]  F. Hadizadeh,et al.  Synthesis of α-[5-(5-amino-1,3,4-thiadiazol-2-yl)-2-imidazolylthio]acetic acids , 2008 .

[49]  Mojahidul Islam,et al.  Synthesis and antimicrobial activity of some novel oxadiazole derivatives. , 2008, Acta Poloniae Pharmaceutica - Drug Research.

[50]  Patrícia Cardoso Perez,et al.  Protein kinases as targets for antiparasitic chemotherapy drugs. , 2007, Current drug targets.

[51]  Jean-Pierre Gotteland,et al.  Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase. , 2005, Journal of medicinal chemistry.

[52]  L. Schang.  Cyclin-dependent kinases as cellular targets for antiviral drugs. , 2002, The Journal of antimicrobial chemotherapy.

[53]  D. Williams,et al.  Recent kinase and kinase inhibitor X-ray structures: mechanisms of inhibition and selectivity insights. , 2004, Current medicinal chemistry.

[54]  R. Goldman,et al.  Discovery and validation of new antitubercular compounds as potential drug leads and probes. , 2009, Tuberculosis.

[55]  L. Bukowski.  Synthesis and some reactions of 2-cyanomethylimidazo [4,5-b]pyridine. Tuberculostatic investigations of obtained compounds. , 1986, Polish journal of pharmacology and pharmacy.

[56]  M. Ali,et al.  Synthesis and Anti Tuberculostatic Activity of Novel 1,3,4‐Oxadiazole Derivatives , 2007 .

[57]  Stefan Wetzel,et al.  ATP competitive inhibitors of D-alanine-D-alanine ligase based on protein kinase inhibitor scaffolds. , 2009, Bioorganic & medicinal chemistry.

[58]  E. AUGUSTYNOWICZ-KOPEĆ,et al.  Synthesis and tuberculostatic activity of some (4-phenylpiperazin-1-ylmethyl)-1,3,4-oxadiazole and (4-phenylpiperazin-1-ylmethyl)-1,2,4-triazole derivatives. , 2004, Acta Poloniae Pharmaceutica - Drug Research.

[59]  M. Michaelis,et al.  Structure-activity relationships of novel heteroaryl-acrylonitriles as cytotoxic and antibacterial agents. , 2008, European journal of medicinal chemistry.

[60]  J. Sawlewicz,et al.  Reactions of cyanomethylbenzimidazoles. Part III. Reaction of cyanomethylbenzimidazoles with isocyanates and isothiocyanates. , 1976, Polish journal of pharmacology and pharmacy.

[61]  W. F. de Azevedo,et al.  Protein-drug interaction studies for development of drugs against Plasmodium falciparum. , 2009, Current drug targets.

[62]  Peter M Fischer,et al.  Strategies for the design of potent and selective kinase inhibitors. , 2005, Current pharmaceutical design.

[63]  S. Strittmatter,et al.  Rho-Associated Kinase II (ROCKII) Limits Axonal Growth after Trauma within the Adult Mouse Spinal Cord , 2009, The Journal of Neuroscience.

[64]  G. C. Rock,et al.  Studies on the mechanisms responsible for variable toxicity of azinphosmethyl to various larval instars of the tufted apple budmoth, Platynota idaeusalis , 1983 .

[65]  Lynn Rasmussen,et al.  Antituberculosis activity of the molecular libraries screening center network library. , 2009, Tuberculosis.